Navigation Links
Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
Date:5/21/2008

nsidered before initiating therapy.

About HUMIRA

In addition to its use in Crohn's disease, HUMIRA is also approved by the FDA for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HUMIRA is indicated as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older.

HUMIRA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis. HUMIRA is also indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

HUMIRA resembles antibodies normally found in the body. It works by blocking tumor necrosis factor alpha (TNF-alpha), an inflammatory protein that, when produced in excess, plays a key role in the inflammatory responses of some autoimmune diseases.

To date, HUMIRA has been approved in 75 countries and more than 250,000 patients worldwide are currently being treated with HUMIRA. Clinical trials are currently under way evaluating the potential of HUMIRA in other immune-mediated diseases.

Abbott's Commitment to Immunology

Abbott is focused on the discovery and development of innovative treatments for immunologic diseases.

More information about HUMIRA, including full prescribing information and Medication Guide, is available on the Web sit
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
3. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
4. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
5. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
6. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
7. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
10. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
11. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 2014 /PRNewswire-iReach/ -- CaPtivate Pharmaceuticals LLC, a ... phosphate (CaP)-based nanoparticle drug and vaccine delivery technologies, ... License Agreement with Immunotope Inc., another ... for the treatment and prevention of viral infections ... of the agreement, Immunotope is granted a non-exclusive ...
(Date:9/15/2014)... , Sept. 15, 2014 PDL BioPharma, Inc. (PDL) ... has paid the September 12, 2014, regular quarterly dividend payment ... of PDL as of September 5, 2014, the record date. ... BioPharma manages a portfolio of patents and royalty assets, ... patents and license agreements with various biotechnology and pharmaceutical ...
(Date:9/15/2014)... DUBLIN , Sept. 15, 2014 ... "Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014" ... (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 presents comprehensive ... Europe , Asia , ... The report includes paracetamol (acetaminophen) description, covers its ...
Breaking Medicine Technology:CaPtivate Pharmaceuticals Enters License Agreement With Immunotope 2CaPtivate Pharmaceuticals Enters License Agreement With Immunotope 3PDL BioPharma Completes Regular Quarterly Dividend Payment 2Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 2Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 3
(Date:9/16/2014)... 16, 2014 DiaperBuys, a national online ... Aging’ Month this September. Healthy Aging Month was started ... the nation on the positive aspects of growing older. ... conditions or side effects from medications that cause urinary ... Manager for DiaperBuys.com. “This can seem daunting to some ...
(Date:9/16/2014)... 16, 2014 Banish headaches forever with ... approved Cefaly device for chronic migraine relief and treatment. ... the United States. Until now, US patients would directly ... in Belgium and wait 2-3 weeks for their device ... United States and once prescription and payment is received, ...
(Date:9/16/2014)... Reading, MA (PRWEB) September 16, 2014 ... announce its partnership with Fairfax Egg Bank. The collaboration ... and expand the donor egg offering at the Fertility ... operated since 2006 and offers the nation’s largest selection ... is advantageous for several reasons:, , ...
(Date:9/15/2014)... (PRWEB) September 16, 2014 The team ... Carey Danis & Lowe report that the ... was found responsible for the injuries that a woman ... to treat stress urinary incontinence (SUI). , Carey Danis ... medical device litigation and personal injury law. The St. ...
(Date:9/15/2014)... 2014 Hastings and Hastings, an experienced ... announces one flat attorney fee for personal injury cases. ... the largest portion possible of their settlement or recovery ... and damaged personal property. In addition, Hastings and Hastings ... simply states that no fees are due unless a ...
Breaking Medicine News(10 mins):Health News:DiaperBuys Honors ‘Healthy Aging’ Month throughout September 2Health News:DiaperBuys Honors ‘Healthy Aging’ Month throughout September 3Health News:Cefaly Migraine Treatment Device Now Readily Available For Widespread Purchase in United States 2Health News:FCNE Announces Partnership with Fairfax Egg Bank 2Health News:Carey Danis & Lowe Reports On $73 Million Boston Scientific Verdict 2Health News:Hastings And Hastings Announces One Flat Attorney Fee For Personal Injury Cases 2Health News:Hastings And Hastings Announces One Flat Attorney Fee For Personal Injury Cases 3
... , SAN BERNARDINO, Calif., Aug. 11 ... its customers and employees recently raised $266,429.00 to benefit the Leukemia ... has raised over $460,000 for this organization. , , ... the month of June 2009, Stater Bros., customers and employees at ...
... , WASHINGTON, Aug. 11 Even while ... is showing hospitals owned and operated by physicians among the best in the ... of "healthcare reform." , , The independent testing and research ... patients around the country. Overwhelmingly, Cons u mer ...
... Labopharm Inc. (TSX: DDS; NASDAQ: DDSS ) ... the U.S. Food and Drug Administration,s (FDA) complete response ... trazodone. , As previously announced, Labopharm received a complete ... indicating the Company,s new drug application (NDA) for its ...
... public survey conducted in Europe found that the vast ... and prostate cancer screening, according to a new study ... the National Cancer Institute . Gerd Gigerenzer, of ... and colleagues conducted a survey of over 10,200 people ...
... , , , , ... SCOR ), a leader in measuring the digital world, today ... the effects of increasing U.S. unemployment on online consumer activity. While ... substantial declines, there has been a corresponding increase in the number ...
... Healthcare reform has become a hot button issue for politicians and ... clear the air and separate fact from fiction. , , ... e QtY97yVQFUg6so , , ... and unrestricted use at http://www.medi a ...
Cached Medicine News:Health News:Stater Bros. Raises $266,429.00 for the Leukemia & Lymphoma Society 2Health News:Physician Owned and Operated Hospitals Get Top Rankings From Consumer Reports, but They Remain on the Healthcare Reform Chopping Block 2Health News:Physician Owned and Operated Hospitals Get Top Rankings From Consumer Reports, but They Remain on the Healthcare Reform Chopping Block 3Health News:Labopharm submits response to FDA for novel antidepressant 2Health News:Health Insurance Provider Sites Attract Fewer U.S. Visitors as Unemployment Increases 2Health News:Health Insurance Provider Sites Attract Fewer U.S. Visitors as Unemployment Increases 3
... The R4Mplus offers global companies ... help meet RFID compliance initiatives. With ... a variety of connectivity options, and ... is a super value. Plus, the ...
... The 105SL combines enhanced memory, ... rugged and reliable all-metal construction. ... processing and print speed make ... users who value reliability, productivity, ...
... R4Mplus offers global companies a cost-effective ... RFID compliance initiatives. With die-cast metal ... of connectivity options, and complex multi-language ... super value. Plus, the fully integrated ...
... Ideal for patient wristband printing, the ... reliable and accurate scanning for improved patient ... text, and graphics on a variety of ... printer prints patient ID wristbands on demand. ...
Medicine Products: